Genetic Technologies Ltd
ASX:GTG

Watchlist Manager
Genetic Technologies Ltd Logo
Genetic Technologies Ltd
ASX:GTG
Watchlist
Price: 0.039 AUD Market Closed
Market Cap: 52.1m AUD

Genetic Technologies Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Genetic Technologies Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Genetic Technologies Ltd
ASX:GTG
Free Cash Flow
-AU$5.8m
CAGR 3-Years
6%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Proteomics International Laboratories Ltd
ASX:PIQ
Free Cash Flow
-AU$6.6m
CAGR 3-Years
-22%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
T
Trajan Group Holdings Ltd
ASX:TRJ
Free Cash Flow
AU$6.7m
CAGR 3-Years
N/A
CAGR 5-Years
48%
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Free Cash Flow
AU$1.5m
CAGR 3-Years
-4%
CAGR 5-Years
29%
CAGR 10-Years
6%
Genetic Signatures Ltd
ASX:GSS
Free Cash Flow
-AU$13.2m
CAGR 3-Years
N/A
CAGR 5-Years
-2%
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Free Cash Flow
AU$4.1m
CAGR 3-Years
29%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Genetic Technologies Ltd
Glance View

Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.

GTG Intrinsic Value
0.027 AUD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Genetic Technologies Ltd's Free Cash Flow?
Free Cash Flow
-5.8m AUD

Based on the financial report for Dec 31, 2024, Genetic Technologies Ltd's Free Cash Flow amounts to -5.8m AUD.

What is Genetic Technologies Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
7%

Over the last year, the Free Cash Flow growth was 25%. The average annual Free Cash Flow growth rates for Genetic Technologies Ltd have been 6% over the past three years , -2% over the past five years , and 7% over the past ten years .

Back to Top